Mushtaq Ahmed, MD
Pulmonary Disease · Bakersfield, CANPI 1033137591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 419 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by GSK at 24.8% of the total.
Across 419 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Boehringer Ingelheim$2K
- AstraZeneca$1K
- Inspire Medical Systems, Inc.$548
- Sanofi$506
- United Therapeutics Corporation$378
- plus $3K from 29 others
Across 15 payments — averaging $3630.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$29K
- AstraZeneca$10K
- Hoffmann-la Roche Limited$10K
- Janssen Research & Development, LLC$5K
What the payments were for
- Food & beverage$9,685100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 138 | $2,409 |
| Boehringer Ingelheim | 46 | $1,586 |
| AstraZeneca | 70 | $1,436 |
| Inspire Medical Systems, Inc. | 6 | $548 |
| Sanofi | 16 | $506 |
| United Therapeutics Corporation | 10 | $378 |
| Grifols USA, LLC | 13 | $337 |
| Amgen(2 entities) | 31 | $336 |
| Regeneron Healthcare Solutions, Inc. | 9 | $245 |
| Mayne Pharma Commercial LLC | 1 | $175 |
| Baxter Healthcare | 7 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $156 |
| Insmed, Inc. | 6 | $152 |
| Verona Pharma, Inc. | 4 | $120 |
| Vanda Pharmaceuticals Inc. | 6 | $117 |
| Pulmonx Corporation | 6 | $116 |
| Angiodynamics, Inc. | 2 | $115 |
| Pfizer | 5 | $112 |
| Advanced Respiratory, Inc | 7 | $111 |
| Merck | 4 | $96 |
| Electromed, Inc. | 6 | $70 |
| Apria Healthcare LLC | 3 | $62 |
| Mylan Specialty L.p. | 3 | $53 |
| Vifor Pharma, Inc. | 2 | $51 |
| AbbVie(2 entities) | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Resmed Corp | 1 | $32 |
| Novo Nordisk | 1 | $24 |
| Bayer | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$371
- TRELEGY ELLIPTA$225
- Inspire$195
- DORYX$175
- Inspire Upper Airway Stimulation System$160
- DUPIXENT$140
- NUCALA$125
- BREZTRI$124
- AREXVY$120
- TEZSPIRE$112
How this compares
$9,719 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 605 | $420,098 |
| OfevNintedanib Esylate | 27 | $344,999 |
| OzempicSemaglutide | 84 | $79,793 |
| TezspireTezepelumab-Ekko | 12 | $51,667 |
| EliquisApixaban | 62 | $51,544 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $45,179 |
| Ambrisentan | 21 | $39,649 |
| Spiriva RespimatTiotropium Bromide | 67 | $34,806 |
| MounjaroTirzepatide | 32 | $33,666 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $31,511 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 53 | $24,671 |
| XareltoRivaroxaban | 16 | $20,229 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $17,821 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 510 | $16,171 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $14,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,409 | $525,946872 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $1,586 | $404,476147 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Farxiga | $1,436 | $88,740110 claims |
| Novo NordiskOzempic | $24 | $79,79384 claims |
| PfizerEliquis | $112 | $51,54462 claims |
| Lilly USA, LLCMounjaro | $38 | $33,66632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Bakersfield
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.